On the morning of November 5, the opening ceremony for the “Biomedical Industry CTO Executive Education and Innovation Strategy Demonstration Base” and Seminar on the Cultivation of Leader Talents in Cell and Gene Therapy Technology hosted by Shanghai International School of Chief Technology Officer (hereinafter referred to as “CTO School”) of East China Normal University, Shanghai BRL Medicine Co., Ltd. (hereinafter referred to as “BRL Medicine”), the Asia Europe Business School of East China Normal University and East China Normal University-University of Haifa Joint Translational Science and Technology Research Institute (hereinafter referred to as “Joint Research Institute”) was successfully held in Building A2, Zizhu International Education Park, Minhang District, Shanghai.
He Jiaxun, Executive Dean of the CTO School and Chinese Dean of Asia Europe Business School, and Xi Zaixi, Founder and CEO of BRL Medicine, respectively signed the “School-enterprise Strategic Cooperation Agreement” on behalf of Shanghai International School of Chief Technology Officer of the East China Normal University and Shanghai BRL Medicine Co., Ltd. Next, He Jiaxun, Xi Zaixi, Liu Mingyao and Gao Yang jointly unveiled the “Biomedical Industry CTO Executive Education and Innovation Strategy Demonstration Base”. Subsequently, He Jiaxun awarded industry mentor certificates to the enterprise executives of BRL Medicine, including Xi Zaixi, Gao Yang, Zhang Jiqin, Tan Binghe, Huang Anling and Xu Nan.
Xi Zaixi delivered a keynote speech entitled “Firm Practitioners in the Context of Cancer Inclusive Cure”.
In the Seminar on the Cultivation of Leader Talents in Cell and Gene Therapy Technology, the participating enterprise executives and the faculty team held a heated discussion on the theme of the cultivation of technology management talents in biomedical field through the integration of industry and education. Xi Zaixi and other BRL Medicine executives talked about the pain points of the enterprise and the demand for technical management talents. Wang Xuehua and other faculties of the Asia Europe Business School put forward the School's ideas and needs in talent cultivation and scientific research cooperation. Xi Zaixi pointed out that the executives of BRL Medicine has the need to learn management concepts, and has a lot of demands for overseas high-level talents to develop international business. He hoped to combine the cutting-edge theory with front-line practice together with the CTO School to polish CTO executive training courses. BRL Medicine could provide business mentors, student employment and other support. Asia Europe Business School, with all degree programs taught in English, has attracted international students from 46 countries in the five years since it was founded, and could support the overseas talent demand of BRL Medicine, He Jiaxun said. Based on common ideas and in combination with enterprise practical experience and teaching advantages of the school, CTO School and BRL Medicine promoted the establishment of multi-dimensional cooperation in executive education, curriculum development, think tank research and integration of industry and education with the “Biomedical Industry CTO Executive Education and Innovation Strategy Demonstration Base” cooperated by both sides as the platform, so as to solve the development problems of science and innovation enterprises, which set an example and a benchmark for the industry, and promoted the innovation and development of science and innovation education.